Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pulmonx (LUNG) Current Deferred Revenue (2019 - 2025)

Historic Current Deferred Revenue for Pulmonx (LUNG) over the last 7 years, with Q3 2025 value amounting to $100000.0.

  • Pulmonx's Current Deferred Revenue fell 825.69% to $100000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $100000.0, marking a year-over-year decrease of 825.69%. This contributed to the annual value of $135000.0 for FY2024, which is 2980.77% up from last year.
  • Latest data reveals that Pulmonx reported Current Deferred Revenue of $100000.0 as of Q3 2025, which was down 825.69% from $100000.0 recorded in Q2 2025.
  • Pulmonx's Current Deferred Revenue's 5-year high stood at $200000.0 during Q3 2021, with a 5-year trough of $100000.0 in Q1 2021.
  • Moreover, its 5-year median value for Current Deferred Revenue was $107000.0 (2023), whereas its average is $120473.7.
  • As far as peak fluctuations go, Pulmonx's Current Deferred Revenue surged by 10000.0% in 2021, and later tumbled by 4700.0% in 2022.
  • Over the past 5 years, Pulmonx's Current Deferred Revenue (Quarter) stood at $200000.0 in 2021, then plummeted by 40.0% to $120000.0 in 2022, then dropped by 13.33% to $104000.0 in 2023, then increased by 29.81% to $135000.0 in 2024, then dropped by 25.93% to $100000.0 in 2025.
  • Its Current Deferred Revenue stands at $100000.0 for Q3 2025, versus $100000.0 for Q2 2025 and $128000.0 for Q1 2025.